Cargando…

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing. Methods: COVID-19 positive patients admitted to the h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karolyi, Mario, Omid, Sara, Pawelka, Erich, Jilma, Bernd, Stimpfl, Thomas, Schoergenhofer, Christian, Laferl, Hermann, Seitz, Tamara, Traugott, Marianna, Wenisch, Christoph, Zoufaly, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282360/ https://www.ncbi.nlm.nih.gov/pubmed/34276386 http://dx.doi.org/10.3389/fphar.2021.704767

Ejemplares similares

Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort
por: Karolyi, Mario, et al.
Publicado: (2020)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
por: Karolyi, M., et al.
Publicado: (2022)

COVID-19 is not “just another flu”: a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria
por: Pawelka, Erich, et al.
Publicado: (2021)

Correction to: COVID-19 is not “just another flu”: a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria
por: Pawelka, Erich, et al.
Publicado: (2021)

Late onset pulmonary embolism in young male otherwise healthy COVID-19 patients
por: Karolyi, M., et al.
Publicado: (2020)

Comparison of clinical characteristics among patients infected with alpha vs. delta SARS-CoV-2 variants
por: Rumpf, Benedikt, et al.
Publicado: (2022)

Rapid Detection of Bacterial and Fungal Pathogens Using the T2MR versus Blood Culture in Patients with Severe COVID-19
por: Seitz, Tamara, et al.
Publicado: (2022)

Clinical and Angiographic Features in Three COVID-19 Patients with Takotsubo Cardiomyopathy. Case Report
por: Hoepler, Wolfgang, et al.
Publicado: (2021)

COVID-19-associated myoclonus in a series of five critically ill patients
por: Grieb, Alexander, et al.
Publicado: (2021)

Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort
por: Karolyi, Mario, et al.
Publicado: (2022)

Detection of bacteria via multiplex PCR in respiratory samples of critically ill COVID-19 patients with suspected HAP/VAP in the ICU
por: Karolyi, Mario, et al.
Publicado: (2021)

Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients: A propensity score matched analysis
por: Karolyi, Mario, et al.
Publicado: (2022)

Is there a clinical difference between influenza A and B virus infections in hospitalized patients?: Results after routine polymerase chain reaction point-of-care testing in the emergency room from 2017/2018
por: Karolyi, Mario, et al.
Publicado: (2019)

Diagnosis of COVID-19 using multiple antibody assays in two cases with negative PCR results from nasopharyngeal swabs
por: Traugott, Marianna Theresia, et al.
Publicado: (2020)

Evaluation of Five Commercial SARS-CoV-2 Antigen Tests in a Clinical Setting
por: Seitz, Tamara, et al.
Publicado: (2022)

Age Related Differences in Monocyte Subsets and Cytokine Pattern during Acute COVID-19—A Prospective Observational Longitudinal Study
por: Pirabe, Anita, et al.
Publicado: (2021)

Immunoglobulin G production in COVID-19 - associations with age, outcome, viral persistence, inflammation and pro-thrombotic markers
por: Pirabe, Anita, et al.
Publicado: (2023)

Platelet Phenotype Analysis of COVID-19 Patients Reveals Progressive Changes in the Activation of Integrin αIIbβ3, F13A1, the SARS-CoV-2 Target EIF4A1 and Annexin A5
por: Ercan, Huriye, et al.
Publicado: (2021)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Successful management of the first reported case in Austria of COVID-19 with ARDS
por: Seitz, T., et al.
Publicado: (2020)

Human recombinant soluble ACE2 in severe COVID-19
por: Zoufaly, Alexander, et al.
Publicado: (2020)

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy
por: Ye, Linhu, et al.
Publicado: (2021)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
por: Russo, Vincenzo, et al.
Publicado: (2020)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
por: Huang, Yin-Qiu, et al.
Publicado: (2020)

Platelets and Antiplatelet Medication in COVID-19-Related Thrombotic Complications
por: Schrottmaier, Waltraud C., et al.
Publicado: (2022)

Adverse Outcome in COVID-19 Is Associated With an Aggravating Hypo-Responsive Platelet Phenotype
por: Schrottmaier, Waltraud C., et al.
Publicado: (2021)

Monkeypox associated acute arthritis
por: Fonti, Mirella, et al.
Publicado: (2022)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison
por: Gagliardini, Roberta, et al.
Publicado: (2021)

Muscle involvement in SARS‐CoV‐2 infection
por: Pitscheider, Lea, et al.
Publicado: (2020)

miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir
por: Bresciani, Elena, et al.
Publicado: (2019)

Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
por: Su, Bin, et al.
Publicado: (2019)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_693ft9lude9r9osogk5svmjdas